These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism. Stein CA J Natl Cancer Inst; 1996 Apr; 88(7):391-3. PubMed ID: 8618230 [No Abstract] [Full Text] [Related]
9. [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results]. Büchele T Onkologie; 2003 Dec; 26 Suppl 7():60-9. PubMed ID: 14716145 [TBL] [Abstract][Full Text] [Related]
10. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Klasa RJ; Gillum AM; Klem RE; Frankel SR Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702 [TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854 [No Abstract] [Full Text] [Related]
12. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654 [TBL] [Abstract][Full Text] [Related]
13. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Ramanarayanan J; Hernandez-Ilizaliturri FJ; Chanan-Khan A; Czuczman MS Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355 [TBL] [Abstract][Full Text] [Related]
14. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483 [TBL] [Abstract][Full Text] [Related]
15. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406 [TBL] [Abstract][Full Text] [Related]
19. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy? Stewart A Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683 [No Abstract] [Full Text] [Related]
20. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Frankel SR Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]